Progesterone
Oral progesterone capsules have defined endometrial-hyperplasia prevention and amenorrhea uses.
FDA-approved product context
Oral progesterone capsules have defined endometrial-hyperplasia prevention and amenorrhea uses.
Reviewed October 10, 2026. Product and route distinctions stay attached to the source; this is not a treatment recommendation.
Evidence and source limits
The retrieved oral capsule label identifies prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving conjugated estrogen tablets, and secondary amenorrhea. The source identifies ANDA marketing status.
The displayed label retains estrogen-plus-progestin warnings and contraindications. Read its exact formulation and warning text rather than assuming all progesterone products or compounded creams share an approval or indication.
Approval applies to the specific labeled product, route and indication, not every preparation of this ingredient or a wellness mixture. Read the original full label and discuss individual circumstances with a medical professional. No dosing or preparation instructions are included.
Original source: Progesterone ↗
Interpretation is limited to the source linked above. Educational source review, not independent medical review. No dosing, preparation instructions, seller links or treatment endorsement.